Parametric Portfolio Associates LLC Has $76.07 Million Stock Holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH)

Parametric Portfolio Associates LLC grew its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 646,042 shares of the medical equipment provider’s stock after purchasing an additional 25,859 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.31% of Zimmer Biomet worth $76,065,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in ZBH. Personal Wealth Partners acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $26,000. TRUE Private Wealth Advisors acquired a new position in Zimmer Biomet during the 2nd quarter worth approximately $26,000. Coastal Investment Advisors Inc. raised its stake in Zimmer Biomet by 271.0% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 187 shares during the period. Private Ocean LLC raised its stake in Zimmer Biomet by 34.8% during the 2nd quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 80 shares during the period. Finally, Rational Advisors LLC raised its stake in Zimmer Biomet by 1,665.2% during the 2nd quarter. Rational Advisors LLC now owns 406 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 383 shares during the period. 89.39% of the stock is currently owned by institutional investors.

In other Zimmer Biomet news, VP Chad F. Phipps sold 7,000 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $138.28, for a total transaction of $967,960.00. Following the completion of the transaction, the vice president now directly owns 37,722 shares of the company’s stock, valued at $5,216,198.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Didier Deltort sold 360 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the transaction, the insider now directly owns 1,194 shares of the company’s stock, valued at $166,264.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,391 shares of company stock valued at $5,642,274. 0.72% of the stock is owned by corporate insiders.

A number of research analysts recently weighed in on ZBH shares. Cowen set a $140.00 price target on Zimmer Biomet and gave the stock a “hold” rating in a research note on Friday, July 26th. Credit Suisse Group increased their price objective on Zimmer Biomet from $101.00 to $120.00 and gave the stock an “underperform” rating in a research note on Monday, July 29th. Robert W. Baird raised Zimmer Biomet from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $132.00 to $154.00 in a research note on Monday, July 29th. Jefferies Financial Group increased their price objective on Zimmer Biomet from $150.00 to $167.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. They noted that the move was a valuation call. Finally, ValuEngine downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $142.26.

Shares of ZBH stock traded down $3.56 during trading on Friday, hitting $139.05. The company’s stock had a trading volume of 471,657 shares, compared to its average volume of 905,914. The company has a market cap of $28.44 billion, a PE ratio of 18.20, a P/E/G ratio of 2.48 and a beta of 1.15. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The business has a fifty day moving average of $136.59 and a 200-day moving average of $125.34. Zimmer Biomet Holdings Inc has a 52 week low of $96.99 and a 52 week high of $143.00.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.02. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The business had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same period in the prior year, the company earned $1.92 earnings per share. Zimmer Biomet’s revenue was down .9% compared to the same quarter last year. As a group, research analysts predict that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Friday, September 27th. Zimmer Biomet’s dividend payout ratio (DPR) is 12.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: What are the advantages to having securities held in street name?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit